Skip to main content

Advertisement

Table 1 Technical validation cohort of healthy donors

From: An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity

Median age (range) in years 33 (21; 64)
Gender, N (%)
 Male 11 (24.4%)
 Female 34 (75.6%)
CMV serostatus, N (%)
 Positive 32 (71.1%)
 Negative 13 (28.9%)